Urology Trials

A list of our early phase urology trials which are open to recruitment at University College London Hospitals

To find more information on UCLH Early Phase Cancer Clinical Trials, including eligibility criteria, click the听hyperlinked听Local Project Reference (LRP)听ID, which will take you to the UCLH Find a Study database.

Additional early phase clinical trials recruiting Urology听cohorts may be found in the听Advanced Solid Tumour Trials Portfolio page.

听

DURANCE DURANCE: 听A phase Ib/II study to assess the safety and activity of DURvalumab (MEDI4736) in combination with S-488210/S-488211 vAccine in Non-muscle invasive bladder CancEr
Local Project Reference:
Principal Investigator:	Dr. Mark Linch
Drug Class/ Treatment:	Durvalumab (PD-L1 Blocking IgG1 Kappa Monoclonal Antibody)听+听S-488210/S-488211 (Peptide Vaccine)
Patient Population:	Non-Muscle Invasive Bladder Cancer
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)

ABACUS-2 ABACUS-2: 听Phase 2 study of neoadjuvant immune checkpoint inhibitors in urothelial cancer
Local Project Reference:
Principal Investigator:	Dr. Mark Linch
Drug Class/ Treatment:	Atezolizumab听(IgG1 Isotype Monoclonal Antibody against PD-L1)
Patient Population:	Patient requiring surgery with: Cohort 1: T1 high grade - T4a of the bladder with mixed (dominant) or rare histological subtype Cohort 2: Upper urinary tract (high grade or high risk)
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)

听

911爆料网

Urology Trials

A list of our early phase urology trials which are open to recruitment at University College London Hospitals

DURANCE

ABACUS-2

Principal Investigator(s):

Dr. mark linch

Dr.听Anuradha Jayaram